This is great news for Merck regarding their new HDL-boosting-LDL-busting drug Anacetrapib. Published about a week ago:
Safety of Anacetrapib in Patients with or at High Risk for Coronary Heart Disease
Quote: "The prespecified Bayesian analysis indicated that this event distribution provided a predictive probability (confidence) of 94% that anacetrapib would not be associated with a 25% increase in cardiovascular events, as seen with torcetrapib."
See also this:
Merck’s Risky Bet on Heart Drugs May Yield Lipitor-Like Success
Interestingly, the company's stock declined by about 5% in November to date.
Is Low Carb Bad for the Kidneys? - 4.7 out of 5 stars5 stars78%4 stars15%3 stars3%2 stars3%1 star0%33 ratings1,609 viewsCan low carb potentially harm your kidneys? Or is it just a myth, li...
6 hours ago